SGLT2 Inhibitor Type 2 Diabetes Drugs

Patients diagnosed with Type 2 diabetes are sometimes administered a new generation of prescription medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors, which includes Invokana, Farxiga, Invokamet, Jardiance, Xigduo XR and Glyxambi. What many diabetic individuals don’t know however, is that SGLT2 inhibitors have been linked to an increased risk of potentially deadly side effects, including diabetic ketoacidosis (DKA), heart attack, cardiovascular problems and kidney failure. If you took Invokana or another SGLT2 inhibitor drug in the past, and you have since suffered a major side effect like ketoacidosis, contact a reputable drug injury attorney today to discuss the possibility of filing a claim against the drug manufacturing company.

SGLT2 Inhibitor Lawsuit // Ford & Associates Nationwide

Types of SGLT2 Inhibitor Drugs

The very first SGLT2 inhibitor to garner approval by the U.S. Food and Drug Administration (FDA) was Invokana in 2013, and a number of similar medications have entered the market for consumer use in the years since. Some of the most popular brand-name SGLT2 inhibitor medications include the following:

Invokana (canagliflozin) – Approved by the FDA in March 2013, and manufactured by Johnson & Johnson’s Janssen Pharmaceuticals subsidiary.

Farxiga (dapagliflozin) – Approved by the FDA in January 2014, and manufactured by Bristol-Myers Squibb and AstraZeneca Pharmaceuticals.

Invokamet (canagliflozin/metformin) – Approved by the FDA in August 2014, and manufactured by Janssen Pharmaceuticals.

Jardiance (empagliflozin) – Approved by the FDA in August 2014, and manufactured by Boehringer Ingelheim.

Xigduo XR (dapagliflozin/metformin) – Approved by the FDA in October 2014, and manufactured by AstraZeneca.

Glyxambi (empagliflozin/linagliptin) – Approved by the FDA in February 2015, and manufactured by Boehringer Ingelheim and Eli Lilly and Company.

Side Effects Linked to SGLT2 Inhibitors

SGLT2 inhibitor drugs are designed to be used in combination with diet and exercise to improve glycemic control in adults with Type 2 diabetes, which, over time, can increase the risk for serious complications like blindness, heart disease, and nerve and kidney damage. However, research has shown that the very drugs that are intended to protect diabetes patients from suffering these serious complications may expose users to side effects that are equally as devastating, including diabetic ketoacidosis, kidney failure, heart attack and death. On May 15, 2015, the FDA issued a drug safety communication warning consumers and the medical community that SGLT2 inhibitors may put patients at risk for dangerously high levels of toxic acids in the bloodstream called ketones, which can lead to ketoacidosis if left untreated.

Ketoacidosis is a severe medical condition characterized by symptoms like nausea, vomiting, breathing problems, confusion, abdominal pain, and unusual fatigue or sleepiness. This recent SGLT2 inhibitor warning was issued after a search of the FDA’s Adverse Event Reporting System turned up 20 cases of acidosis identified as diabetic ketoacidosis, ketoacidosis or acidosis in diabetes patients treated with SGLT2 inhibitors from March 2013 to June 6, 2014. All of the patients involved in the reports required emergency room visits or hospitalization to treat the acidosis. In the drug safety communication, the FDA indicated that, since June 2014, the agency has continued to receive adverse event reports for DKA and ketoacidosis in patients treated with Invokana and other SGLT2 inhibitors.

Contact an Experienced SGLT2 Inhibitor Lawyer Today

Type 2 diabetes is the most common form of the chronic disease, impacting roughly 24 million people and accounting for more than 90% of diabetes cases diagnosed in the United States. Unfortunately, an examination of adverse event reports submitted to the FDA suggests that new-generation diabetes drugs like Invokana and Invokamet may put Type 2 diabetes patients at risk for diabetic ketoacidosis and other potentially life-threatening side effects. If you have been diagnosed with DKA, kidney failure or a heart attack, and you believe an SGLT2 inhibitor to be the cause, consult a knowledgeable product liability lawyer today for legal help. With a qualified attorney on your side, you can protect your legal rights and seek fair and timely reimbursement for your losses.

SGLT2 Inhibitors (a class of type 2 diabetes drugs) are linked to major side effects including kidney failure and diabetic ketoacidosis // Ford & Associates Nationwide

Check out all the latest news on SGLT2 Inhibitor Type 2 Diabetes Drugs Lawsuits >>

Additional SGLT2 Resources

Invokana – WebMD

Diabetes in Control – FDA Warns that Use of SGLT-2 Inhibitors Could Lead to Ketoacidosis in Some Patients’

CALL US NOW Free Online Case Review